Cannabis Science, Inc., is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. The Company is engaged in medical marijuana research and development. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).
|Headquarters||Suite B #254, 6946 North Academy Blvd|
COLORADO SPRINGS, CO, United States 80918
|President, Interim Chief Financial Officer, Director||Robert Melamede|
|Chief Executive Officer, Director||Dorothy Bray|
|Chief Operating Officer||Moe Afaneh|
|General Corporate Counsel, Director||Chad Johnson|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||684.3M||Book Value||$0.00|
|Cannabis Science Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.